MRK - Merck & Co., Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

MRK

MERCK & CO., INC.

NYSE

$144.84

▲ UP 0.63% (0.91)

KEY STATISTICS

Market Cap$355.49 B

52w High$156.92

52w Low$77.58

Dividend Yield2.61%

FrequencyQuarterly

P/E45.12

Volume7.38M

Shares Out.2.47B

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Robert Davis

COMPENSATION 2026

Salary$1,645,302

Stock Awards$12,102,838

Incentive Plan Pay$2,326,500

All Other Comp.$658,058

Total$20,797,845

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 13, 1978

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

74,000

PRICE TARGET

Target High$180.00

Target Low$105.00

Target Median$161.00

Target Consensus$158.12

UPCOMING EARNINGS

DateOct 29, 2026

DayThursday

Rev. Est.$17.32B

OCT

THU

SPLIT RECORD

DATE	TYPE	RATIO
2021-06-03	Forward	131:125
1999-02-17	Forward	2:1
1992-05-26	Forward	3:1
1988-05-26	Forward	3:1
1986-05-27	Forward	2:1
1972-06-01	Forward	2:1
1964-05-27	Forward	3:1

PRICE

$144.84 ▲ UP 0.63% (+$0.91)

OVERLAYS

About Merck & Co., Inc.

https://www.merck.com ↗

Merck & Co. is a global healthcare company offering pharmaceuticals in oncology, immunology, vaccines, and neuroscience, along with veterinary health solutions, serving diverse healthcare providers and collaborating with major partners.

INDUSTRY

Drug Manufacturers - General

A PRODUCT MERCK & CO., INC. IS KNOWN FOR

Keytruda (pembrolizumab)

Keytruda is a leading immunotherapy drug used to treat a wide variety of cancers. As a PD-1 inhibitor, it helps the body's own immune system to detect and fight cancer cells, making it a cornerstone of modern oncology and Merck's top-selling product.